Whitepaper

BD Libertas™ effectively delivers dose volumes up to 5 mL subcutaneously

Download

PDF 13.0 MB

BD Libertas™ effectively delivers dose volumes up to 5 mL subcutaneously

New clinical trial data demonstrates the performance of BD Libertas™ Wearable Injector. A detailed analysis of the BD independently sponsored and conducted study has been published in Clinical and Translational Science (5 Dec 2020).

https://drugdeliverysystems.bd.com/contact-us

BD, the BD Logo and Libertas are trademarks of Becton, Dickinson and Company or its affiliates © 2021 BD. All rights reserved. 

Other Content from SAS BECTON DICKINSON FRANCE